



CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

July 22, 2026

LARGO, Fla.--(BUSINESS WIRE)--Jul. 22, 2026-- CONMED Corporation (NYSE: CNMD) today announced that its [AirSeal® Robotic Solution](#) is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform ("dV5"). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive's portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems.

Building on the existing indication for Intuitive's da Vinci 8mm round cannulas, AirSeal Robotic Solution is now also indicated for use with the 8mm hex cannula. The expanded indication reinforces the clinical and commercial benefits of AirSeal within robotic surgery by supporting compatibility with Intuitive's latest platform architecture and enabling hospitals and surgeons to use complementary technologies with greater clarity. Backed by over 40 clinical studies demonstrating the benefits of AirSeal at low insufflation pressures, the AirSeal Robotic Solution is intended to help enhance patient outcomes, support procedural efficiency, and strengthen CONMED's differentiated position in a growing robotic surgery market.

"We are pleased to secure and announce this expanded indication for use, which was supported by extensive engineering and technical compatibility testing conducted by CONMED in collaboration with Intuitive," said Patrick J. Beyer, CONMED's President and Chief Executive Officer. "These efforts reflect our commitment to ensuring surgeons and hospitals are supported with the requisite compatibility data and clear product communication, while ultimately empowering them to achieve quality care for patients."

Mr. Beyer continued: "We expect this expanded indication for use to provide clarity in the marketplace on how AirSeal and the da Vinci 5 platform work together to support consistent surgical workflows and facilitate positive patient outcomes. Importantly, achieving this milestone gives us further confidence in the compelling growth opportunity for our AirSeal portfolio."

About the AirSeal Robotic Solution

The [AirSeal® Robotic Solution](#) is an advanced insufflation solution comprised of an AirSeal® Cannula Cap, AirSeal® and Bifurcated Tube Set designed for use within the da Vinci robotic surgical environment. The AirSeal Robotic Solution is functionally equivalent to AirSeal® access ports delivering the same stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation while working entirely through robotic ports.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. CONMED's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260722411813/en/>

CONMED Corporation

Dalton Henry
Investor Relations Analyst
IR@conmed.com

Source: CONMED Corporation